Professor

Andrew Wilks

FAA FTSE FAHMS

Andrew Wilks
Image Description
Andrew Wilks is an molecular biologist and cancer cell biologist. Working at the Ludwig Institute for Cancer Research (Melbourne) from 1988 to 1998, he led the Growth Regulation Laboratory. He and his laboratory made transformative discoveries in the signal transduction field as well as in neurogenesis and angiogenesis. Wilks has completed a rare “trifecta” – discovering and patenting a number of important drug discovery targets (viz. JAK1 and JAK2) and defining their role(s) in cytokine signalling; founding one of Australia’s most successful biotech companies, Cytopia; and co‐inventing and leading the team that delivered the therapeutic JAK inhibitor, momelotinib.

Fields of research

31 BIOLOGICAL SCIENCES
  • 3101 BIOCHEMISTRY AND CELL BIOLOGY
    • 310111 Signal Transduction
32 BIOMEDICAL AND CLINICAL SCIENCES
  • 3211 ONCOLOGY AND CARCINOGENESIS
    • 321101 Cancer Cell Biology
    • 321104 Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
    • 321108 Molecular Targets
  • 3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES
    • 321402 Clinical Pharmacology and Therapeutics
34 CHEMICAL SCIENCES
  • 3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY
    • 340406 Molecular Medicine

For full list of research codes, please visit the ARC Website .

Expertise type

  • Structure-based Inhibitor Design
  • Corporate Leadership
  • Biology
  • Drug Design
  • Immune-oncology
  • Drug Discovery
  • Research Commercialisation
  • Signalling Pathways

Please contact fellowship@science.org.au to request any updates to the data.